1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-K/A
AMENDMENT NO. 1
X Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange
- --- Act of 1934 (No Fee Required, Effective October 7, 1996)
For the fiscal year ended December 31, 1996
------------------
Transition Report Pursuant to Section 13 or 15(d) of the Securities
- --- Exchange Act of 1934 (No Fee Required)
For the transition period from ______________to____________
Commission File No. 0-20619
-------
MATRIA HEALTHCARE, INC.
(Exact name of registrant as specified in its charter)
Delaware 58-2205984
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
1850 Parkway Place, 12th Floor 30067
Marietta, Georgia (Zip Code)
(Address of principal executive offices)
Registrant's telephone number, including area code (770) 423-4500
The Registrant hereby files this Form 10-K/A to amend its Annual Report on
Form 10-K for the fiscal year ended December 31, 1996 to include the information
required by Part III (Items 10, 11, 12 and 13) in lieu of the incorporation
thereof by reference from the Registrant's definitive proxy statement for its
Annual Meeting of Shareholders.
2
PART III
ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT
The Board of Directors of the Company is composed of three classes of
directors (Class I, II & III), elected for staggered three year terms
commencing in 1996, 1997 and 1998, respectively. In connection with the merger
of Tokos Medical Corporation, a Delaware corporation ("Tokos"), and Healthdyne,
Inc., a Georgia corporation ("Healthdyne") with and into the Company on March
8, 1996 (the "Merger"), one-half of the original directors were nominated by
Healthdyne and the other half by Tokos. For a period of three years following
the Merger and continuing through the Company's 1998 Annual Meeting of
Stockholders, (i) any vacancy on the Board of Directors, or any committee
thereof, arising among the Tokos nominated directors and any nominee selected
to fill a director position occupied by a Tokos nominated director is to be
filled or selected by the remaining Tokos nominated directors and (ii) any
vacancy on the Company's Board of Directors, or any committee thereof, arising
among the Healthdyne nominated directors and any nominee selected to fill a
director position occupied by a Healthdyne nominated director is to be filled or
selected by the remaining Healthdyne nominated directors.
The names of the current directors and executive officers, their ages as of
April 1, 1997 and certain other information about them are set forth below.
NAME AGE POSITION WITH THE COMPANY
------------------- --- ----------------------------------------------------
Parker H. Petit (1) 57 Chairman of the Board
Frank D. Powers 48 Executive Vice President
J. Brent Burkey 50 Senior Vice President, General Counsel and Secretary
Donald R. Millard (1) 49 Senior Vice President - Finance, Chief Financial
Officer and Treasurer
Timothy R. Busch 42 Director
Robert F. Byrnes (1) 52 Director
Craig T. Davenport 44 Director
Thomas W. Erickson 46 Director
David L. Goldsmith 47 Director
Carl E. Sanders 71 Director
Jackie M. Ward 58 Director
Morris S. Weeden 77 Director
Frederick P. Zuspan, 75 Director
M.D.
- ------------------
PARKER H. PETIT. Mr. Petit has been Chairman of the Board of Matria since
the Merger on March 8, 1996. (See Footnote 1 below). Mr. Petit was also the
founder of and was employed by Healthdyne as its Chairman of the Board of
Directors and Chief Executive Officer from 1970 to March 1996. Mr. Petit is
also Chairman of the Board of Healthdyne Technologies, Inc. and Healthdyne
Information Enterprises, Inc. and is a director of Atlantic Southeast Airlines,
Inc. and Intelligent Systems, Inc.
- ------------------
(1) Pending the election of a new President and Chief Executive Officer, two
directors (Messrs. Petit and Byrnes) and one executive officer (Mr. Millard)
have performed such duties on an interim basis on behalf of the Company as part
of a three-person Office of the President.
2
3
FRANK D. POWERS. Mr. Powers has been Executive Vice President of Matria
since March 8, 1996. Prior thereto, he served as President of Healthdyne
Maternity Management, a subsidiary of Healthdyne, from October 1989 until March
1996, and as President of Healthdyne's Home Care Group from November 1986 to
October 1989. In addition, he was President of Healthdyne's Home
Care Products Division from September 1984 to November 1986 and Corporate
Controller of Healthdyne from January 1983 to September 1984.
J. BRENT BURKEY. Mr. Burkey has served as Senior Vice President, General
Counsel and Secretary of the Company since March 8, 1996. Prior thereto, he
served as Senior Vice President and General Counsel of Healthdyne from
September 1987 to March 1996 and as Vice President and General Counsel of
Healthdyne from November 1982 to September 1987. He also served as Secretary
of Healthdyne from August 1984 to March 1996 and as Assistant Secretary of
Healthdyne from November 1982 to August 1984.
DONALD R. MILLARD. Mr. Millard has served as Senior Vice
President-Finance, Chief Financial Officer and Treasurer of the Company since
March 8, 1996. (See Footnote 1 on page 2 infra). Prior thereto, he served as
Vice President-Finance and Chief Financial Officer of Healthdyne from July 1987
to March 1996 and, in addition, was Treasurer of Healthdyne from March 1990 to
March 1996. Prior thereto, he was President of Dental One, Inc., a dental
healthcare provider, from December 1982 to June 1987. Mr. Millard is also a
director of Coast Dental Services, Inc.
TIMOTHY R. BUSCH. Mr. Busch has served as a director of Matria since
April 25, 1997 when he was elected by the Tokos nominated directors to fill the
vacancy created by the resignation of Mr. Gene P. Guselli. Since December
1979, Mr. Busch has been a certified public accountant, attorney and President
of The Busch Firm, an estate planning and transactional law firm, based in
Irvine, California that has provided tax and estate planning legal advice to
Mr. Byrnes. Two limited partnerships in which Mr. Busch was a general partner
filed petitions in 1993 and 1994, respectively, for bankruptcy protection under
the Federal bankruptcy laws.
ROBERT F. BYRNES. Mr. Byrnes has served as a director of Matria since
March 8, 1996. Mr. Byrnes also served as President and Chief Executive Officer
of Matria from March 1996 to December 1996. (See Footnote 1 on page 2 infra).
Prior to the Merger, he served as Chief Executive Officer of Tokos since
July 1984, as Chairman of the Board since November 1987 and as President and
Chief Operating Officer of Tokos from January 1994 to March 1996.
CRAIG T. DAVENPORT. Mr. Davenport has served as a director of Matria
since March 8, 1996 and formerly was a director of Tokos from November 1986 to
March 1996 and a consultant to Tokos through December 1994. Since August 1994
he has been Chief Executive Officer and Managing Partner for The D.W. Group, a
private investment firm which provides advisory services for early stage and
emerging growth healthcare companies. Mr. Davenport served as Chief Operating
Officer of Tokos from November 1986 to December 1993, and as President of Tokos
from November 1987 to December 1993. Mr. Davenport is also a director of
TheraTx, Inc.
THOMAS W. ERICKSON. Mr. Erickson has served as a director of Matria since
March 8, 1996 and formerly was a director of Tokos from 1985 to 1996. Mr.
Erickson has been President and Chief Executive Officer of CareSelect Group,
Inc., a physician practice management company since July
3
4
1994. Mr. Erickson has also served as President and Chief Executive Officer of
Erickson Capital Group, Inc., a private investment firm, which invests in a
wide range of healthcare service companies and managed care alliances.
DAVID L. GOLDSMITH. Mr. Goldsmith has served as a director of Matria
since March 8, 1996 and formerly was a director of Tokos from 1985 to 1996.
Mr. Goldsmith has been a managing director of Robertson Stephens & Co. since
1992, and a partner of Robertson Stephens from 1981 to 1992. In addition, Mr.
Goldsmith directs the Robertson Stephens' venture capital and management buyout
activity. Mr. Goldsmith is also a director of Apria Healthcare, Inc. and
Spectranetics, Inc.
CARL E. SANDERS. Mr. Sanders has served as a director of Matria since
March 8, 1996 and formerly was a director of Healthdyne from 1986 to 1996. Mr.
Sanders, a former governor of the State of Georgia, is Chairman of Troutman
Sanders LLP, an Atlanta based law firm which provides legal services to Matria.
Mr. Sanders is also a director of Carmike Cinemas, Inc., Metromedia
International Group, Inc., Norrell Corporation, Roadmaster Industries, Inc. and
Healthdyne Information Enterprises, Inc.
JACKIE M. WARD. Ms. Ward has served as a director of Matria since March
8, 1996 and is President and Chief Executive Officer of Computer Generation
Incorporated, a privately-held, Atlanta based corporation engaged in designing
and producing "turnkey" computer hardware and software systems for
telecommunications and other specialized applications, which she founded in
1968. Ms. Ward is also a former Chairperson of the Board of Regents of the
University System of Georgia and the current Chairman of the Metro Atlanta
Chamber of Commerce, as well as a director of SCI Systems, Inc., Trigon Blue
Cross Blue Shield and Nations Bank, N.A. and a member of several other civic
and government organizations.
MORRIS S. WEEDEN. Mr. Weeden has served as a director of Matria since
March 8, 1996 and formerly was a director of Healthdyne from 1987 to 1996. Mr.
Weeden is retired. He was Vice Chairman--Board of Directors of Morton Thiokol,
Inc., a salt, chemical, household and aerospace products manufacturer, from
March 1980 to December 1984. Prior thereto, Mr. Weeden was Executive Vice
President of Morton Norwich Products, Inc., in charge of pharmaceutical
operations, President of Morton International, a pharmaceutical division of
Morton Norwich Products, Inc. and President of Bristol Laboratories, a
pharmaceutical division of Bristol Myers Corp.
FREDERICK P. ZUSPAN, M.D. Dr. Zuspan has served as a director of Matria
since March 8, 1996, formerly was a director of Healthdyne from 1993 to 1996
and has been a physician since 1951. Dr. Zuspan has been Professor and
Chairman Emeritus, Department of Obstetrics and Gynecology at the Ohio State
University College of Medicine since July 1991 and Editor-in-Chief of the
American Journal of Obstetrics and Gynecology since 1991. Dr. Zuspan was
previously Professor of the Ohio State University College of Medicine from 1987
to 1991 and Professor and Chairman of the Department of Obstetrics and
Gynecology at the Ohio State University College of Medicine from 1975 to 1987,
at the University of Chicago, Pritzker School of Medicine from 1966 to 1975,
and at the Medical College of Georgia from 1960 to 1966.
4
5
SECTION 16 REPORTS
Section 16(a) of the Securities Exchange Act of 1934 requires the
Company's directors and officers, and persons who own more than 10% of a
registered class of the Company's equity securities, to file with the
Commission initial reports of ownership and reports of changes in ownership of
equity securities of the Company. Officers, directors and greater than 10%
shareholders are required by the Commission regulations to furnish the Company
with copies of all Section 16(a) forms they file.
To the Company's knowledge, based solely on review of the copies of such
reports furnished to the Company for the fiscal year ended December 31, 1996,
all Section 16(a) filing requirements applicable to its officers, directors and
greater than 10% shareholders were properly filed.
5
6
ITEM 11. EXECUTIVE COMPENSATION
The following table sets forth compensation paid to the five most highly
compensated executive officers (the "Named Executive Officers") for their
services in all capacities to the Corporation and its subsidiaries from
March 8, 1996 (the effective date of the merger of Tokos and Healthdyne) to
December 31, 1996:
SUMMARY COMPENSATION TABLE
- --------------------------------------------------------------------------------------------------------------------
LONG-TERM
COMPENSATION
ANNUAL COMPENSATION AWARDS
------------------- ------------
ALL OTHER
NAME AND COMPENSA-
PRINCIPAL POSITION YEAR SALARY ($) BONUS ($) OPTIONS (#) TION ($)
- ----------------------------------------------------------------------------------------------------
Parker H. Petit (1) 1996 $204,711 $-- -- $ 3,750 (2)
Chairman of the Board
Robert F. Byrnes (3) 1996 274,970 -- 60,000 1,028,940 (4)
President and Chief Executive Officer
Terry P. Bayer (5) 1996 184,819 -- 40,000 3,750 (2)
Executive Vice President
Frank D. Powers 1996 181,923 -- 40,000 3,750 (2)
Executive Vice President
J. Brent Burkey 1996 170,769 -- 30,000 3,750 (2)
Senior Vice President, General
Counsel and Secretary
- ---------------------------
(1) Mr. Petit terminated his employment with the Company for "good reason"
effective December 31, 1996, but remains as Chairman of the Board of
Directors in his capacity as a director. His termination entitles him
to severance compensation payable in future periods. See "Change of
Control Severance Agreements" herein.
(2) Represents the Company's matching contributions to the named executive
officers under the Company's tax-qualified 401 (k) Profit Sharing Plan
accrued during 1996.
(3) The Employment Agreement, dated as of May 1, 1995, as amended, between
Mr. Byrnes and Tokos under which Mr. Byrnes was employed as President and
Chief Executive Officer of the Company expired at the end of its stated
term on December 31, 1996 without renewal, entitling Mr. Byrnes to
severance compensation payable in future periods in accordance with the
terms thereof. See "Change of Control Severance Agreements" herein.
(4) Subject to an obligation to repay under certain circumstances, the
Compensation Committee of the Board of Directors on March 28, 1996 agreed
to reimburse Mr. Byrnes, in addition to the relocation expenses and closing
costs on the primary residence covered by the standard relocation policy
of the Company, for the excess of the cost and expenses invested by him
in his residence in Villa Park,
6
7
California and condominium in Palm Springs, California over the expected
selling price thereof in order to induce him to relocate his residence to
the Marietta, Georgia metropolitan area. The aggregate amount of this
reimbursement was $1,025,190 and is included above. Although he sold both
California properties, Mr. Byrnes did not relocate his residence to
Marietta, Georgia. Also includes $3,750 representing the Company's
matching contribution to Mr. Byrnes under the Company's tax-qualified
401(k) Profit Sharing Plan accured during 1996. See "Change of Control
Severance Agreements" herein.
(5) The Employment Agreement, dated as of January 1, 1995, as amended,
between Ms. Bayer and Tokos under which Ms. Bayer was employed as an
Executive Officer of the Company expired at the end of its stated term on
December 31, 1996, without renewal entitling Ms. Bayer to severance
compensation payable in future periods in accordance with the terms
thereof. See "Change of Control Severance Agreements" herein.
7
8
STOCK OPTIONS
The following table contains information as of the end of the last
fiscal year concerning the grant of stock options under Matria's 1996 Stock
Incentive Plan to the Named Executive Officers of the Company.
OPTION GRANTS IN LAST FISCAL YEAR
- -----------------------------------------------------------------------------------------------
INDIVIDUAL GRANTS POTENTIAL REALIZABLE
VALUE AT ASSUMED
% OF TOTAL ANNUAL RATES OF
OPTIONS EXERCISE STOCK PRICE APPRECI-
GRANTED TO OR ATION FOR OPTION
OPTIONS EMPLOYEES BASE TERM
GRANTED IN FISCAL PRICE EXPIRATION
NAME #(1) YEAR ($/SH) DATE 5% 10%
- -----------------------------------------------------------------------------------------------
Parker H. Petit -0- -0- -- -- -- --
Robert F. Byrnes 60,000 6.62% $8.50 3/28/2006 $321,000 $812,808
Terry P. Bayer 40,000 4.41% 8.50 3/28/2006 214,000 541,872
Frank D. Powers 40,000 4.41% 8.50 3/28/2006 214,000 541,872
J. Brent Burkey 30,000 3.31% 8.50 3/28/2006 160,500 406,404
- -------------------
(1) These options to purchase the Company's Common Stock were granted on
March 28, 1996. For each option granted, 33% of the shares subject to the
option grants become exercisable in cumulative increments on the first,
second and third anniversary date of the option grants. The options each
have a term of ten years from the date of grant and are not transferable,
otherwise than by will or the laws of descent and distribution. Except as
provided in each of the option agreements, the options may not be
exercised unless employment with the Company or an affiliate or subsidiary
continues. Options granted under the plans will expire (i) immediately
upon the employee's termination for good cause; (ii) three months after
the date of termination for reason other than good cause; (iii) three
months after the employee's voluntary termination; (iv) one year after the
employee's death or disability; or (v) ten years from the date of the
grant, whichever shall occur first. The purchase price of the shares
subject to these options may be paid (i) in cash, (ii) through the
surrender of previously owned stock of Matria, or (iii) a combination of
cash and previously owned stock of Matria. The optionees are obligated
to reimburse Matria at the time of any exercises of the options for any
taxes required to be withheld by Matria under federal, state or local
law as the result of the exercise of the options.
STOCK OPTION EXERCISES
The following table sets forth information with respect to the Named
Executive Officers concerning the exercise of options from March 8, 1996
through December 31, 1996 and unexercised options held as of the end of the
fiscal year:
8
9
AGGREGATED OPTION EXERCISES IN LAST FISCAL YEAR
AND FY - END OPTION VALUES
- -------------------------------------------------------------------------------------------------------------------------
NUMBER OF UNEXERCISED VALUE OF UNEXERCISED IN-
OPTIONS AT THE-MONEY OPTIONS AT
LAST FISCAL YEAR END(#) LAST FISCAL YEAR END(#) (1)
--------------------------- ------------------------------
SHARES VALUE
NAME ACQUIRED REALIZED
ON EXERCISE (MARKET PRICE AT
(#) EXERCISE LESS EXERCISE PRICE) EXERCISABLE UNEXERCISABLE EXERCISABLE UNEXERCISABLE
- -------------------------------------------------------------------------------------------------------------------------
Parker, H. Petit -0- $- 146,667 - $307,619 $ -
Robert F. Byrnes -0- - 200,000 60,000 37,500 -0-
Terry P. Bayer -0- - 155,000 40,000 -0- -0-
Frank D. Powers -0- - 52,667 40,000 99,795 -0-
J. Brent Burkey -0- - 85,000 30,000 164,026 -0-
(1) Based on $4.75, the last sale price of the Company's Common Stock on
December 31, 1996.
COMPENSATION OF DIRECTORS
Directors who are employees of the Company receive no additional
compensation for serving on the Board of Directors. Directors who are not
employees receive a fee of $3,000 per quarter, plus $1,000 for each Board
meeting and $750 for each Committee meeting attended on a day other than a
Regular Meeting of the Board, and are reimbursed for any travel expenses
incurred. The Chairman of the Board, in lieu of the above retainer and meeting
fees, is paid a fee of $12,500 per quarter.
CHANGE OF CONTROL SEVERANCE AGREEMENTS
Prior to the Merger of Healthdyne and Tokos with and into Company, Tokos
and Healthdyne had certain Change of Control Agreements with the Named
Executive Officers, the terms of which were assumed by the Company, as follows:
Tokos: During 1994 and 1995, Tokos entered into employment agreements
with Mr. Byrnes, Ms. Bayer and certain other officers of Tokos who did not
become executive officers of the Company. These agreements provided for
severance payments and certain benefits in the event of a voluntary or
involuntary termination upon a "change of control," a "termination for failure
to renew" and a "termination other than for cause." The executive officers
were not entitled to any compensation or benefits if they were "terminated for
cause." A "termination for failure to renew" meant a failure to renew or
extend the term of the agreement beyond the December 31, 1996 termination date
or any extension thereof. A "termination other than for cause" was defined as
constructive termination of the executive officer or material breach of the
employment agreement by Tokos. A "termination for cause" was defined as a
termination for any willful dishonesty towards, fraud upon or deliberate injury
to Tokos by the executive officer.
Amendments to the employment agreements described above were approved by
Tokos and executed on October 2, 1995, and become effective on March 8, 1996,
the effective date of the Merger. The amendments increased the amount of
severance and other cash compensation payable in the event of a termination
upon a "change of control" or "termination for failure to renew" from 18 months
9
10
continuation of salary plus 150% of the highest bonus earned by the employee,
to an amount equal to three times the executive officer's average annual base
salary and other income derived from Tokos, or the Company, which is reportable
for federal tax purposes for the five years ending prior to the date of
termination. The amount of severance payable under the employment agreements
is limited to amounts which are deductible by Matria under Section 280G of the
Internal Revenue Code. In addition, the covenants against competition and
soliciting customers and employees included in the employment agreements were
revised to provide greater protection to Tokos.
The employment agreements of Ms. Bayer and Mr. Byrnes were not renewed by
the, Board of Directors of the Company and expired at the end of their stated
term on December 31, 1996, thereby entitling both employees to severance
compensation based upon a "termination for failure to renew." At the
suggestion of Mr. Byrnes, the Board of Directors of the Company, in return for
an agreement by Ms. Bayer to continue her employment beyond the expiration of
the employment agreement for a limited period of time, agreed to accelerate the
payment of Ms. Bayer's severance and other cash compensation into a lump sum
amount payable upon the termination of such additional employment period. On
or about March 14, 1997, Ms. Bayer's employment was terminated and she was paid
$701,606 in cash compensation as severance and an agreement not to compete, and
she was provided with a continuation for a three year period of time of the
fringe benefits to which she was entitled under the Employment Agreement.
As a result of the failure to renew his employment agreement, Mr. Byrnes'
employment with the Company terminated on December 31, 1996 and he became
entitled to cash compensation for severance and an agreement not to compete in
an amount of $1,799,899, payable in equal monthly installments over a three
year period, plus a continuation for a three year period of the fringe benefits
to which he was entitled under the employment agreement. Mr. Byrnes has, among
other things, requested the Company to adjust the time period serving as the
basis for the severance calculation, which would have the effect of increasing
the amount payable thereunder and to honor a request for a lump sum, as opposed
to installment, payment of the amount due.
Healthdyne: In February 1988, Healthdyne entered into agreements with
Messrs. Petit and Burkey entitling such executive officers to certain
benefits upon specified terminations of employment within three years following
a "change in control" of Healthdyne. The Merger, as well as several other
transactions engaged in by Healthdyne prior to the Merger, constituted a
"change in control" under these agreements. Each agreement provided that in
the event of a "change in control" of Healthdyne, the executive officer
concerned would be entitled to certain benefits upon his subsequent termination
of employment during the term of the agreement unless such termination is (i)
because of his death disability or retirement, (ii) by the Company for cause,
or (iii) with respect to termination by the executive officer, other than for
"good reason." Under these agreements, a number of circumstances entitle the
executive officer to treat a good faith termination on his part as being a
termination for "good reason." These include an adverse change in the
executive officer's compensation, discontinuation of certain benefits, the
assignment of duties inconsistent with his status or duties in effect
immediately prior to the "change in control," the relocation of the principal
executive office to a location outside of Marietta, Georgia or requiring the
executive officer to be based anywhere other than the Company's principal
executive office.
Under the agreements, if an executive officer's employment with the
Company terminates following the consummation of a "change in control" other
than under the circumstances set forth in clauses (i), (ii), or (iii) of the
preceding paragraph, the executive officer will be entitled to receive his full
base salary through the date of termination and a lump sum severance payment
equal to three times the executive officer's average annual salary and other
income derived from Healthdyne or the Company, which is reportable for federal
tax purposes for the five years ending prior to the date of
10
11
termination. In addition, such executive officer will be entitled to receive,
for a period of three years after the date of termination, all life, disability
and health insurance coverage, automobile allowances and other fringe benefits
equivalent to those in effect at the date of termination and is entitled to
receive additional amounts, if any, relating to any excise taxes imposed on
the executive officer as a result of Section 280G of the Internal Revenue Code.
Healthdyne entered into amended and restated agreements with each of the
executive officers mentioned above and a new agreement with Frank D. Powers
(the "Restated Agreements") upon the effective date of the Merger, which
superseded the prior agreements described above. The Restated Agreements do
not increase the amount of compensation payable upon a "change of control", but
they do acknowledge that the Merger constituted a "change in control," as
defined in the Restated Agreements, and extend the term of the Restated
Agreements from a term ending in February 1997 to a term ending three years
after the Merger. In addition, under the Restated Agreements the executive
officer agrees to comply with certain protective covenants not to compete
which, for a period of three years following the later of the effective time of
the merger, or the effective time of any other "change in control" of the
Company that occurs within three years after the effective date of the merger
and during the executive officer's continued employment with the Company,
prohibit the executive officer from competing with the Company, soliciting
customers or personnel of the Company. The Restated Agreements otherwise are
substantially similar to the change in control agreements previously in effect.
Mr. Petit, the Chairman of the Board of Directors, terminated his
employment as an employee of the Company for "good reason" in December 1996 and
became entitled to receive compensation in the amount of $4,307,600 under his
Restated Agreement, plus a continuation of his fringe benefits for a period of
three years. Although entitled by the express terms of his Agreement to a
lump sum payment of this amount, Mr. Petit voluntarily agreed to accept
payments in annual installments over a three year period.
PENSION PLAN
The following table shows the estimated pension benefits payable to a
covered participant at normal retirement age under the Company's nonqualified
pension plan which provides benefits based on remuneration that is covered under
the plan and years of service with the Company and its affiliates.
PENSION PLAN TABLE
Years of Services
Remuneration 10 15 20 25 30 35
------------ -- -- -- -- -- --
$75,000 $ 7,000 $18,250 $ 29,500 $ 29,500 $ 29,500 $ 29,500
100,000 14,500 29,500 44,500 44,500 44,500 44,500
125,000 22,000 40,750 59,500 59,500 59,500 59,500
150,000 29,500 52,000 74,500 74,500 74,500 74,500
175,000 37,000 63,250 89,500 89,500 89,500 89,500
200,000 44,500 74,500 104,500 104,500 104,500 104,500
11
12
Remuneration covered by the benefit award is based on the average base
salary of the executive for the three years in which his base salary is the
highest. This amount for each of the Named Executive Officers participating in
the plan as of the end of the last fiscal year was $370,417, $266,640,
$218,667, $166,700 and $206,060, for Mr. Petit, Mr. Byrnes, Ms. Bayer, Mr.
Powers and Mr. Burkey, respectively. The estimated years of service for each
Named Executive Officer as of the end of the last fiscal year was 24 years for
Mr. Petit, 16 years for Mr. Byrnes, 6 years for Ms. Bayer, 14 years for Mr.
Powers and 14 years for Mr. Burkey. Benefits shown are computed as a
diminishing single life annuity beginning at age 65 with annual reductions
equal to the annual increases in primary social security benefits.
In the event of a "change of control" of the Company as defined in the
benefit awards, all benefits accrued to date immediately vest and each
Named Executive Officer may require the Company to place in trust for the Named
Executive Officer's benefit an amount of money equal to the present value of
the participant's accrued retirement benefit and, on an annual basis
thereafter, to make additional contributions to such trust for any additional
benefit accruals of the Named Executive Officer. As defined in these awards,
the Merger was deemed to be a "change of control". The Named Executive
Officers who received these benefit awards and the amounts that the Company
would be required to place in trust for each such Named Executive Officer as of
December 31, 1996, if requested thereunder, are as follows: Parker H. Petit -
$998,000; Robert F. Byrnes - $334,000; Terry P. Bayer - $ -0-; Frank D.
Powers - $159,000; and J. Brent Burkey - $242,000.
12
13
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The following table sets forth certain information regarding the
beneficial ownership of the Company's Common Stock as of March 1, 1997 by (i)
each person who is known by the Company to own beneficially more than 5% of the
outstanding shares, (ii) each director of the Company, (iii) each Named
Executive Officer, and (iv) all executive officers and directors as a group.
Unless otherwise indicated, the holders listed below have sole voting and
investment power with respect to all shares beneficially owned by them.
AMOUNT AND NATURE PERCENT
NAME OF BENEFICIAL OWNER OF BENEFICIAL OWNERSHIP (1)(2) OF CLASS (1)(2)
- ------------------------------------- ------------------------------ ---------------
Foreign and Colonial Management 1,954,000 5.4%
Limited and Hypo Foreign & Colonial
Management (Holdings) Limited (3)
Exchange House, Primrose Street
London EC2A2NY England
Parker H. Petit (4) 1,275,581 3.5%
Robert F. Byrnes 1,252,263 3.4%
Timothy R. Busch -0- ----
Terry P. Bayer 168,333 ----
Frank D. Powers 68,436 ----
J. Brent Burkey 111,694 ----
Craig T. Davenport 33,000 ----
Thomas W. Erickson 24,000 ----
David L. Goldsmith 60,182 ----
Carl E. Sanders 64,500 ----
Jackie M. Ward 5,004 ----
Morris S. Weeden 25,000 ----
Frederick P. Zuspan 15,000 ----
All executive officers and directors
as a group (15 persons) 3,249,454 8.9%
- ---------------------------
- -- Less than 1%
(1) Under the rules of the Securities and Exchange Commission (the "SEC"), a
person is deemed to be a beneficial owner of a security if he or she has
or shares the power to vote or to direct the voting of such security, or
the power to dispose or to direct the disposition of such security. A
person is also deemed to be a beneficial owner of any securities of which
that person has the right to acquire beneficial ownership within 60 days
as well as any securities owned by such person's spouse, children or
relatives living in the same house. Accordingly, more than one person may
be deemed to be a beneficial owner of the same securities. Unless
otherwise indicated by footnote, the named individuals have sole voting
and investment power with respect to the shares held by them.
(2) With respect to each person in the table, assumes that such person has
exercised all options, warrants and other rights to purchase Common Stock
exercisable within 60 days beneficially owned by him or that no other
person has exercised any such rights.
13
14
(3) This information is as of the date set forth in and based solely on the
Schedule 13G furnished to the Company by this entity.
(4) Does not include 295,130 shares owned by Bank South, N.A., Atlanta,
Georgia, as Trustee for the benefit of two of Mr. Petit's children. Mr.
Yokubinas, a former officer and a director of Healthdyne, is a member of a
self-perpetuating, three-member advisory committee that has power to
remove the Trustee and to direct the Trustee as to the voting and
disposition of the shares owned by the Trust except that the advisory
committee has no such power during the lifetime of Mr. Petit if the shares
held by Mr. Petit and the trust, when aggregated, are "significant from
the viewpoint of voting control" of the Company. Both the Trustee and the
advisory committee consider the shares owned by the Trustee to be
significant in terms of voting control. In the absence of direction by
the advisory committee, the Trustee has sole power to direct the voting
and disposition of these securities.
ITEM 13. CERTAIN TRANSACTIONS
The following indebtedness formerly due to Tokos and Healthdyne became
payable in accordance with its terms to the Company upon the effective date of
the Merger:
In July 1981, 248,000 shares of common stock reserved under the
Healthdyne 1981 Incentive Stock Option Plan were sold to Parker H. Petit for
$1.33 per share in exchange for $330,000 principal amount of a 8% promissory
note (the "1981 Promissory Note") payable in four years and secured by the
purchased shares. Healthdyne's Board of Directors extended the maturity dates
of the 1981 Promissory Note, forgave interest accrued from July 1985 through
December 1987, and stayed the accrual of any additional interest until the
stock was sold. The maximum outstanding principal indebtedness to the Company
of Mr. Petit since January 1, 1996 was $873,182, of which $325,800 related to
the 1981 Promissory Note, $350,000 to a loan evidenced by a promissory note,
dated September 24, 1992 bearing interest at a floating rate which was 8.25% at
year end, payable on December 31, 1996, $100,000 related to a loan evidenced by
a promissory note, dated March 16, 1993, bearing interest at a floating rate
which was 8.25% at year end, payable on demand, and $125,000 related to a loan
evidenced by a promissory note, dated June 27, 1994, bearing interest at a
floating rate which was 8.25% at year end, payable on demand. In connection
with his termination of employment, Mr. Petit repaid in full all indebtedness
outstanding to the Company on December 31, 1996.
As of December 31, 1996, Robert F. Byrnes was indebted to the Company in
the aggregate amount of $3,414,107 (the maximum amount outstanding in 1996).
The loans are evidenced by a series of promissory notes, bearing interest at 6%
per annum, and are secured by an aggregate of 930,013 shares of Matria common
stock having an aggregate value of $4,417,562 on December 31, 1996 and
$3,720,052 on April 29, 1997. Approximately one-third of such loans represent
interest bearing promissory notes delivered by Mr. Byrnes to Tokos to exercise
stock options issued under Tokos' 1985 and 1995 Stock Option Plans. The
remainder represents interest bearing loans of $1,012,000 and $900,000 advanced
by Tokos to Mr. Byrnes to extinguish a third party debt he initiated to pay the
taxes associated with the stock option exercises. The Board of Directors of
Tokos approved these tax loans so that Mr. Byrnes would not be forced to sell
shares of Tokos stock to repay this tax related debt and extended the maturity
date of all loans to December 31, 1996.
Mr. Byrnes' indebtedness to the Company became due and payable in full on
December 31, 1996, but the payment thereof was deferred by the terms of Section
6 of his employment agreement, dated May 1, 1995, as amended, which provides
that the payment of any loans due and owing by Mr. Byrnes to the Company on the
date of his termination of employment would become due and payable two years
after the effective date of the termination or one year after re-employment,
whichever is sooner. In order to both remain eligible for this payment
deferral and to comply with the
14
15
terms of a security agreement relating to the tax loans, Mr. Byrnes is
obligated to maintain collateral with the Company having a current value equal
to one and one-half times the amount of the loans. On April 18, 1997, the
Company notified Mr. Byrnes that additional collateral (approximately $1.5
million based upon the value of the collateral on April 29, 1997) is necessary
in order to comply with the terms and conditions of the agreements and to
prevent the loans from becoming due and payable. To date, Mr. Byrnes
has not responded to the notification.
Mr. Carl E. Sanders, a director of the Company, is also the Chairman
of Troutman Sanders LLP, a law firm based in Atlanta, Georgia which provided
certain legal services to the Company in fiscal year 1996 and is expected to be
retained by the Company in the future.
SIGNATURE
---------
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this Form 10-K/A to be signed on its behalf by the
undersigned, thereunto duly authorized.
Matria Healthcare, Inc.
Date: April 29, 1997 By /s/ Donald R. Millard
-------------------------------
Donald R. Millard, Senior Vice
President-Finance, Chief
Financial Officer and
Treasurer
15